Experienced in Porphyria

Dr. Racquel D. Innis-Shelton

Birmingham Hematology Oncology Assoc LLC
Alabaster, AL
Experienced
in Porphyria
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Racquel Innis-Shelton is a Hematologist Oncology specialist and a Hematologist in Alabaster, Alabama. Dr. Innis-Shelton and is rated as an Experienced provider by MediFind in the treatment of Porphyria. Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant. Dr. Innis-Shelton is currently accepting new patients.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Student in an Organized Health Care Education/Training Program in VA
Hospital Affiliations
St Vincent's Chilton
Shelby Baptist Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC
1024 1st St N, Alabaster, AL 35007
205-664-4051

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 25, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Enrollment Status: Completed
Publish Date: April 25, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

9 Total Publications

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
Journal: Journal for immunotherapy of cancer
Published: May 25, 2022
Similar Doctors
Expertise in
15
conditions
Dr. Alejandro Garcia-Hernandez
Hematology Oncology | Hematology | Oncology
Expertise in
15
conditions
Dr. Alejandro Garcia-Hernandez
Hematology Oncology | Hematology | Oncology

Southeast Physician Network, P.C.

1410 Mcfarland Blvd N, 
Tuscaloosa, AL 
 (41.9 mi)
205-345-8208
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Alejandro Garcia-Hernandez is a Hematologist Oncology specialist and a Hematologist in Tuscaloosa, Alabama. Dr. Garcia-Hernandez and is rated as an Advanced provider by MediFind in the treatment of Porphyria. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Garcia-Hernandez is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile